The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Incyte; Inovio Pharmaceuticals; Janssen; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
David F. McDermott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Bristol-Myers Squibb; Prometheus (Inst)
 
Philippe Barthelemy
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD; Novartis; Pfizer; Roche
 
Camillo Porta
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Pfizer
 
Saby George
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Exelixis; Genentech/Roche; Janssen Oncology; Novartis; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Frede Donskov
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Asim Amin
Consulting or Advisory Role - Merck
Speakers' Bureau - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Merck
 
Marc-Oliver Grimm
Other Relationship - Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bayer Health; Bristol-Myers Squibb; Hexal; Intuitive Surgical; Ipsen; Janssen-Cilag; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi/Aventis
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck; Pfizer
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
M. Brent McHenry
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Sabeen Fatima Mekan
Employment - Bristol-Myers Squibb
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Hans J. Hammers
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; exelixis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)